LongevityLow Risk

SS-31

Also known as: Elamipretide, Bendavia, MTP-131

Half-life:: ~2-3 hours

Administration Routes

subcutaneous injectionintravenous

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Targets cardiolipin in inner mitochondrial membrane; stabilizes cristae structure; enhances electron transport chain efficiency; reduces mitochondrial ROS

A mitochondria-targeted antioxidant peptide that protects and restores mitochondrial function. Exceptional data for heart failure, Barth syndrome, and age-related mitochondrial decline.

Primary Research Areas

mitochondrial protection
cardioprotection
energy production
anti-aging

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyInvestigational

Mitochondria-targeting tetrapeptide (elamipretide) by Stealth BioTherapeutics. FDA issued CRL for Barth syndrome NDA 2021 (additional data required). Continued by Mitobridge/AstraZeneca. Investigational.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.